[go: up one dir, main page]

WO2004080922A3 - Substituted vitamin d analogues and their therapeutic uses - Google Patents

Substituted vitamin d analogues and their therapeutic uses Download PDF

Info

Publication number
WO2004080922A3
WO2004080922A3 PCT/BE2004/000037 BE2004000037W WO2004080922A3 WO 2004080922 A3 WO2004080922 A3 WO 2004080922A3 BE 2004000037 W BE2004000037 W BE 2004000037W WO 2004080922 A3 WO2004080922 A3 WO 2004080922A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogues
vitamin
therapeutic uses
substituted vitamin
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BE2004/000037
Other languages
French (fr)
Other versions
WO2004080922A2 (en
Inventor
Roger Bouillon
Annemieke Verstuyf
Maurits Vandewalle
Clercq Pierre De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Universiteit Gent
Original Assignee
Katholieke Universiteit Leuven
Universiteit Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven, Universiteit Gent filed Critical Katholieke Universiteit Leuven
Priority to AU2004220477A priority Critical patent/AU2004220477B8/en
Priority to SI200431733T priority patent/SI1601646T1/en
Priority to US10/548,994 priority patent/US20060189576A1/en
Priority to CA002518531A priority patent/CA2518531A1/en
Priority to AT04718886T priority patent/ATE517864T1/en
Priority to PL04718886T priority patent/PL1601646T3/en
Priority to DK04718886.7T priority patent/DK1601646T3/en
Priority to JP2006504039A priority patent/JP2006519788A/en
Priority to EP04718886A priority patent/EP1601646B1/en
Publication of WO2004080922A2 publication Critical patent/WO2004080922A2/en
Publication of WO2004080922A3 publication Critical patent/WO2004080922A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to analogues of vitamin D namely 14-epi-2-alkyl-19-nor vitamin D derivatives. Also a general method for the synthesis and the biological activities are described. The general formula is: (I) where R (α or β oriented) represents an alkyl substituent and X part of a typical side chain of vitamin D or of one of its established analogues.
PCT/BE2004/000037 2003-03-10 2004-03-10 Substituted vitamin d analogues and their therapeutic uses Ceased WO2004080922A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2004220477A AU2004220477B8 (en) 2003-03-10 2004-03-10 2-Substituted vitamin D analogues and their therapeutic uses
SI200431733T SI1601646T1 (en) 2003-03-10 2004-03-10 2-substituted vitamin d analogues and their therapeutic uses
US10/548,994 US20060189576A1 (en) 2003-03-10 2004-03-10 Substituted vitamin d analogues and their therapeutic uses
CA002518531A CA2518531A1 (en) 2003-03-10 2004-03-10 2-substituted vitamin d analogues and their therapeutic uses
AT04718886T ATE517864T1 (en) 2003-03-10 2004-03-10 2-SUBSTITUTED VITAMIN D ANALOGUES AND THEIR THERAPEUTIC APPLICATIONS
PL04718886T PL1601646T3 (en) 2003-03-10 2004-03-10 2-substituted vitamin d analogues and their therapeutic uses
DK04718886.7T DK1601646T3 (en) 2003-03-10 2004-03-10 2-substituted vitamin D analogues and therapeutic uses thereof
JP2006504039A JP2006519788A (en) 2003-03-10 2004-03-10 Vitamin D analogs and their therapeutic use
EP04718886A EP1601646B1 (en) 2003-03-10 2004-03-10 2-substituted vitamin d analogues and their therapeutic uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0305332.9A GB0305332D0 (en) 2003-03-10 2003-03-10 Biological evaluation of novel vitamin D analogues
GB0305332.9 2003-03-10

Publications (2)

Publication Number Publication Date
WO2004080922A2 WO2004080922A2 (en) 2004-09-23
WO2004080922A3 true WO2004080922A3 (en) 2004-12-09

Family

ID=9954381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE2004/000037 Ceased WO2004080922A2 (en) 2003-03-10 2004-03-10 Substituted vitamin d analogues and their therapeutic uses

Country Status (14)

Country Link
US (1) US20060189576A1 (en)
EP (1) EP1601646B1 (en)
JP (1) JP2006519788A (en)
AT (1) ATE517864T1 (en)
AU (1) AU2004220477B8 (en)
CA (1) CA2518531A1 (en)
CY (1) CY1111843T1 (en)
DK (1) DK1601646T3 (en)
ES (1) ES2368064T3 (en)
GB (1) GB0305332D0 (en)
PL (1) PL1601646T3 (en)
PT (1) PT1601646E (en)
SI (1) SI1601646T1 (en)
WO (1) WO2004080922A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006057884A2 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2α-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND THEIR USES
US7241751B2 (en) * 2004-11-22 2007-07-10 Wisconsin Alumi Research Foundation 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and its uses
CA2588396C (en) 2004-11-22 2013-04-23 Wisconsin Alumni Research Foundation 17,20(e)-dehydro vitamin d analogs and their uses
WO2006060885A1 (en) * 2004-12-07 2006-06-15 K.U.Leuven Research & Development 7-(2-cyclohexylidene-ethylidene)-spiro[5.5]undecanes useful for making pharmaceutical compositions
EP1877063A4 (en) * 2005-05-03 2009-11-04 Wisconsin Alumni Res Found COMPOUNDS OF 19,26,27-TRINOR-1ALPHA, 25-DIHYDROXYVITAMIN D3
US7803789B2 (en) 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
US7528122B2 (en) 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
JP2009533483A (en) 2006-04-06 2009-09-17 ウイスコンシン アラムニ リサーチ ファンデーション 2-Methylene-1α, 25-dihydroxy-18,19,21-trinorvitamin D3 and uses thereof
EP2046737B1 (en) 2006-04-06 2011-09-07 Wisconsin Alumni Research Foundation 2-methylene-1 alpha,25-dihydroxy-19,21-dinorvitamin d3 analogs and uses thereof
EP2021320A2 (en) 2006-04-06 2009-02-11 Wisconsin Alumni Research Foundation 2-substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin d analogs and uses thereof
US7741314B2 (en) 2006-09-28 2010-06-22 Wisconsin Alumni Research Foundation 2-Methylene-(20R,25S)-19,27-Dinor-(22E)-Vitamin D Analogs
MX2011012330A (en) * 2009-05-20 2011-12-16 Hybrigenics Sa New therapeutical uses of inecalcitol.
CA2777938C (en) * 2009-10-21 2017-11-14 Wisconsin Alumni Research Foundation Method of preventing type 1 diabetes
US20120015913A1 (en) * 2010-07-15 2012-01-19 Delansorne Remi Formulations of 14-EPI-Analogues of Vitamin D
EP2407152A1 (en) 2010-07-15 2012-01-18 Hybrigenics S.A. Formulations of 14-epi-analogues of vitamin D
BR112013000930A2 (en) 2010-07-15 2017-10-31 Hybrigenics Sa 14-epi analog formulations of vitamin d and cmc
WO2012118154A1 (en) 2011-03-02 2012-09-07 学校法人日本大学 Novel vitamin d receptor modulator with partial agonist activity
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
CN104326922B (en) * 2014-11-03 2016-08-17 成都百裕制药股份有限公司 The preparation method of ticagrelor intermediate (1R, 2S)-2-(2,3-difluorophenyl) cyclopropylamine
JP2025534350A (en) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド Long-acting parathyroid hormone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936105A (en) * 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804502A (en) * 1988-01-20 1989-02-14 Hoffmann-La Roche Inc. Vitamin D compounds
NZ271332A (en) * 1993-07-09 2001-03-30 Theramex Vitamin D analogues and pharmaceutical use
US6806262B2 (en) * 2000-05-31 2004-10-19 Wisconsin Alumni Research Foundation 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936105A (en) * 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
POSNER GARY H ET AL: "2,2-disubstituted analogues of the natural hormone 1alpha,25-dihydroxyvitamin D3: Chemistry and biology", BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 10, no. 7, July 2002 (2002-07-01), pages 2353 - 2365, XP002291417, ISSN: 0968-0896 *
SICINSKI RAFAL R ET AL: "2-Ethyl and 2-ethylidene analogues of 1alpha,25-dihydroxy-19-norvita min D3: Synthesis, conformational analysis, biological activities, and docking to the modeled rVDR ligand binding domain", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 16, 1 August 2002 (2002-08-01), pages 3366 - 3380, XP002291416, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
CA2518531A1 (en) 2004-09-23
DK1601646T3 (en) 2011-10-03
PL1601646T3 (en) 2011-12-30
EP1601646A2 (en) 2005-12-07
CY1111843T1 (en) 2015-10-07
SI1601646T1 (en) 2011-11-30
EP1601646B1 (en) 2011-07-27
AU2004220477A1 (en) 2004-09-23
ATE517864T1 (en) 2011-08-15
ES2368064T3 (en) 2011-11-14
WO2004080922A2 (en) 2004-09-23
US20060189576A1 (en) 2006-08-24
AU2004220477B2 (en) 2010-05-06
JP2006519788A (en) 2006-08-31
AU2004220477B8 (en) 2010-10-14
PT1601646E (en) 2011-09-16
GB0305332D0 (en) 2003-04-09

Similar Documents

Publication Publication Date Title
WO2004080922A3 (en) Substituted vitamin d analogues and their therapeutic uses
WO2004014913A3 (en) Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
WO2006050501A3 (en) Novobiocin analogues as anticancer agents
AU2003218758A1 (en) Derivatives of 1-phenyl-3-phenylpyrazole as herbicides
WO2005074643A3 (en) Benzamide compounds useful as rock inhibitors
WO2001019828A3 (en) Kinase inhibitors as therapeutic agents
CA2492096A1 (en) Cis-alkoxy-substituted spirocyclic 1-h-pyrrolidine-2,4-dione derivatives serving as pesticides
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
ATE377420T1 (en) PHENYLALKANEOUS ACID AND PHENYLOXYALKANEOUS ACID DERIVATIVES AS HPPAR ACTIVators
DK1483245T3 (en) 5-substituted alkylaminopyrazole derivatives as pesticides
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
AU2003237955A8 (en) Phenyloxyalkanonic acid derivatives as hppar activators
WO2006073938A3 (en) Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds
WO2005028474A3 (en) Pyrazoloquinoline derivatives as chk-1 inhibitors
WO2005063786A3 (en) Process for fluorocytidine derivatives
WO2003059875A3 (en) DERIVATIVES OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPARα ACTIVATION
BRPI0412925A (en) nicotinamide derivatives useful as pde4 inhibitors
WO2004056832A3 (en) Epothilone derivatives
AU2003296451A1 (en) Method of reducing toxicity of anticancer agents
WO2005062991A3 (en) Ten and 20-di-esterification derivatives of camptothecins and methods to treat cancers
TW200502204A (en) Oligo acid derivatives
EA200800044A1 (en) DERIVATIVES 2,5-BISDIAMIN [1,4] BENZOHINONA
AU6730600A (en) Vitamin d derivatives having substituents at the 2alpha-position
NO20052593L (en) Continuous process for the preparation of fructopyranose sulfamate derivatives.
WO2005068451A3 (en) Methods for the synthesis of dictyostatin and derivatives and analogues thereof, stereochemical characterisation, novel dictyostatin compounds and uses thereof and synthetic intermediates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004220477

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2518531

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006189576

Country of ref document: US

Ref document number: 10548994

Country of ref document: US

Ref document number: 2006504039

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004718886

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004220477

Country of ref document: AU

Date of ref document: 20040310

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004220477

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004718886

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 10548994

Country of ref document: US